Throughout the month of July, Surfing NASH embarks on a series of episodes dedicated to takeaways emerging from a busy past month at both the 2023 EASL Congress and the American Diabetes Association’s 83rd Scientific Sessions.
For this feature, Sven Francque (University of Antwerp) and Ian Rowe (University of Leeds) join Jörn Schattenberg and Roger Green to discuss a range of fascinating topics to emerge at the EASL Congress meeting held in Vienna.
This conversation begins with Roger’s note of a population study from South Korea looking to identify patients with steatotic liver disease (SLD), but not cirrhosis, that will progress to HCC over a ten year period. After sharing the study details, both Ian and Jörn express common concern around the relatively small size of the identified patient group. Jörn shares his hope that with new disease classification which combines metabolic and alcoholic components we will be able to study these issues more broadly in populations that might be more finely tuned for the study aims. Next, Jörn highlights a paper that leads the group to unpack how little is known about the mechanisms of fibrosis resolution beyond the idea that there are clear differences between the progression and regression processes.
If you have questions or comments around the EASL Congress meeting, new nomenclature, discussed papers or any other topics addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.
Stay Safe and Surf On!